<DOC>
	<DOCNO>NCT00312052</DOCNO>
	<brief_summary>The primary purpose study assess safety tolerability E5555 subject coronary artery disease .</brief_summary>
	<brief_title>Safety Tolerability E5555 Its Effects Markers Intravascular Inflammation Subjects With Coronary Artery Disease</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled trial E5555 , PAR-1 inhibitor . The total duration individual study participation 28 week ( 196 day ) . This included treatment period 24 week ( 168 day ) follow-up period 4 week ( 28 day ) .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Males Females , 45 80 year age 2 . Confirmed coronary artery disease define one following : Postacute coronary syndrome myocardial infarction Post percutaneous coronary intervention coronary artery bypass graft oAngina pectoris document ( electrocardiogram imaging study ) ischemia Angiographically document lesion occlude â‰¥70 % coronary vessel And high risk define one following : Elevated hsCRP ( highsensitivity Creactive protein ) Diabetes mellitus History carotid artery disease and/or peripheral artery disease Thromboembolic transient ischemic attack stroke &gt; 1 year prior screen 3 . All subject must receive low dose aspirin and/or clopidogrel and/or ticlopidine . EXCLUSION CRITERIA 1 . History acquire congenital bleeding disorder , coagulopathy platelet disorder , history pathological bleeding within last 6 month 2 . History intracranial bleeding , history hemorrhagic retinopathy know structural cerebral vascular lesion 3 . Clinically significant hematological , hepatic renal abnormality 4 . Patients specific STsegment change , severe congestive heart failure uncontrolled cardiac arrhythmia baseline 5 . Recent significant ( determined investigator ) cardiovascular event</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Coronary Artery Disease</keyword>
</DOC>